Abstract

Nanoparticle carriers offer the possibility of enhanced delivery of therapeutic payloads in tumor tissues due to tumor-selective accumulation through the enhanced permeability and retention effect (EPR). Gold nanoparticles (AuNP), in particular, possess highly appealing features for development as nanomedicines, such as biocompatibility, tunable optical properties and a remarkable ease of surface functionalization. Taking advantage of the latter, several strategies have been designed to increase treatment specificity of gold nanocarriers by attaching monoclonal antibodies on the surface, as a way to promote selective interactions with the targeted cells—an approach referred to as active-targeting. Here, we describe the synthesis of spherical gold nanoparticles surface-functionalized with an anti-HER2 antibody-drug conjugate (ADC) as an active targeting agent that carries a cytotoxic payload. In addition, we enhanced the intracellular delivery properties of the carrier by attaching a cell penetrating peptide to the active-targeted nanoparticles. We demonstrate that the antibody retains high receptor-affinity after the structural modifications performed for drug-conjugation and nanoparticle attachment. Furthermore, we show that antibody attachment increases cellular uptake in HER2 amplified cell lines selectively, and incorporation of the cell penetrating peptide leads to a further increase in cellular internalization. Nanoparticle-bound antibody-drug conjugates retain high antimitotic potency, which could contribute to a higher therapeutic index in high EPR tumors.

Highlights

  • Most solid malignancies display a tumor microenvironment with increased interstitial fluid pressures (IFP) that significantly impairs tumor penetration of conventional anticancer agents following systemic delivery

  • PEGylation of gold nanoparticles has proven to be highly beneficial in increasing circulation half-life by preventing adhesion of serum proteins that facilitate uptake by the reticuloendothelial system (RES)—an effect that drastically decreases the amount of nanoparticles that can eventually reach the tumor site [31]

  • The construction of a thiol-functionalized PEGylated antibody drug-conjugate (PEGylated Trastuzumab-vcMMAE) proved to yield antibody-drug conjugate (ADC) with conserved high affinity towards the human epidermal growth factor receptor 2 (HER2) receptor; thereby enabling coupling to gold nanoparticles to function as targeting agents carrying a cytotoxic payload

Read more

Summary

Introduction

Most solid malignancies display a tumor microenvironment with increased interstitial fluid pressures (IFP) that significantly impairs tumor penetration of conventional anticancer agents following systemic delivery. Inefficient localization in the target tissue can lead to tumor regions exposed to subtherapeutic doses of the drug, whereby cancer cells can undergo phenotypic alterations that render them resistant to the agent administered [3]. In this context, nanoparticles (NPs) have emerged as drug delivery vehicles that can harness the preferential accumulation of nanosized materials in the tumor due to the well-described enhanced permeability and retention (EPR) effect [4]. Several liposome-encapsulated cytotoxic drugs have received regulatory approval on the basis of superior therapeutic indices relative to the free drug [5]

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call